Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options

Archives of Pathology and Laboratory Medicine

Volumn 139, Issue 5, 2015, Pages 642-649

  Ross, Jeffrey S ^a,b   Badve, Sunil ^c   Wang, Kai ^b   Sheehan, Christine E ^a   Boguniewicz, Ann B ^a   Otto, Geoff A ^b   Yelensky, Roman ^b   Lipson, Doron ^b   Ali, Siraj ^b   Morosini, Deborah ^b   Chliemlecki, Juliann ^b   Elvin, Julia A ^b   Miller, Vincent A ^b   Stephens, Philip J ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b FOUNDATION MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BREAST NEOPLASMS; CANCER GRADING; CARCINOMA; DNA SEQUENCE; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC VARIABILITY; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN; INTRON; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BREAST NEOPLASMS; CARCINOMA; EXONS; FEMALE; GENOMIC STRUCTURAL VARIATION; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INDIVIDUALIZED MEDICINE; INTRONS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM GRADING; SEQUENCE ANALYSIS, DNA;

EID: 84928969113     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2014-0200-OA     Document Type: Article

References (57)

1. Luini A, Aguilar M, Gatti G, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2007;101(3):349-353.
2. Yamaguchi R, Horii R, Maeda I, et al. Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implications. Hum Pathol. 2010;41(5):679-685.
3. Rungta S, Kleer CG. Metaplastic carcinomas of the breast: diagnostic challenges and new translational insights. Arch Pathol Lab Med. 2012;136(8):896-900.
4. Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24(2):157-167.
5. Lee H, Jung SY, Ro JY, et al. Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol. 2012;65(5):441-416.
6. Jung SY, Kim HY, Nam BH, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2000;120(3):627-637.
7. Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10(4):413-419.
8. Tse GM, Tan PH, Putti TC, Lui PC, Chaiwun B, Law BK. Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol. 2006(10);59:1079-1083.
9. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49(1):10-21.
10. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
11. Okada N, Hasebe T, Iwasaki M, et al. Metaplastic carcinoma of the breast. Hum Pathol. 2010;41(7):960-970.
12. Bae SY, Lee SK, Koo MY, et al. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat. 2011;126(2):471-478.
13. Nagao T, Kinoshita T, Hojo T, Tsuda H, Tamura K, Fujiwara Y. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast. 2012;21(3):289-295.
14. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-1281.
15. Chen IC, Lin CH, Huang CS, et al. Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011;130(1):345-351.
16. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-2334.
17. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023-1031.
18. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov. 2013;12(5):358-369.
19. Kamalakaran S, Varadan V, Janevski A, et al. Translating next generation sequencing to practice: opportunities and necessary steps. Mol Oncol. 2013;7(4):743-755.
20. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2009;117(2):273-280.
21. Cooper CL, Karim RZ, Selinger C, Carmalt H, Lee CS, O'Toole SA. Molecular alterations in metaplastic breast carcinoma. J Clin Pathol. 2013;66(6):522-528.
22. Horlings HM, Weigelt B, Anderson EM, et al. Genomic profiling of histological special types of breast cancer. Breast Cancer Res Treat. 2013 Nov; 142(2):257-269.
23. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68. doi:10.1186/bcr2635.
24. Geyer FC, Weigelt B, Natrajan R, et al. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol. 2010;220(5):562-573.
25. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10(6):529-541.
26. Lien HC, Lin CW, Mao TL, Kuo SH, Hsiao CH, Huang CS. p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. J Pathol. 2004;204(2):131-139.
27. Reis-Filho JS, Pinheiro C, Lambros MB, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006;209(4):445-453.
28. Gilbert JA, Goetz MP, Reynolds CA, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 2008;7(4):944-951.
29. Hayes MJ, Thomas D, Emmons A, Giordano TJ, Kleer CG. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res. 2008;14(13):4038-4044.
30. Lin SY, Xia W, Wang JC, et al. b-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A. 2000;97(8):4262-4266.
31. Geyer FC, Lacroix-Triki M, Savage K, et al. b-catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol. 2011;24(2):209-231.
32. Lien HC, Hsiao YH, Lin YS, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene. 2007;26(57):7859-7871.
33. Sarrió D, Rodriguez-Pinalla SM, Hardisson D, et al. Epithelial- mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68(4):989-997.
34. Tomaskovic-Crook E, Thompson EW, Thiery JP. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res. 2009;11(6):213. doi:10.1186/bcr2416.
35. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69(10):4116-4124.
36. Taube JH, Herschkowitz JI, Komurov K, et al. Core epithelial-tomesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A. 2010;107(44):15449-15454.
37. Zhang Y, Toy KA, Kleer CG. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol. 2011;25(2):178-84.
38. Moody SE, Perez D, Pan TC, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005;8(3):197-209.
39. Gwin K, Buell-Gutbrod R, Tretiakova M, Montag A. Epithelial-to-mesenchymal transition in metaplastic breast carcinomas with chondroid differentiation: expression of the E-cadherin repressor Snail. Appl Immunohistochem Mol Morphol. 2010;18(6):526-531.
40. Nassar A, Sookhan N, Santisteban M, et al. Diagnostic utility of snail in metaplastic breast carcinoma. Diagn Pathol. 2010;5:76. doi:0.1186/1746-1596-5-76.
41. Miller VA, Ross JS, Wang K, et al. Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples [abstract]. J Clin Oncol. 2013;31(15):11020.
42. An HX, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol. 1999;154(1):113-118.
43. Węsierska-Gądek J, Kramer MP. The impact of multi-targeted cyclindependent kinase inhibition in breast cancer cells: clinical implications. Expert Opin Investig Drugs. 2011;20(12):1611-1628.
44. Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012;104(6):476-487.
45. Pitts TM, Davis SL, Eckhardt SG, Bradshaw-Pierce EL. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors. Pharmacol Ther. 2014;142(2):258-269.
46. Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18(2):568-576.
47. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550-562.
48. Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005;65(23):10992-11000.
49. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68(15):6084-6091.
50. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(database issue):D945-D950. doi:10.1093/nar/gkq929.
51. Balko JM, Giltnane JM, Wang K, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4(2):232-245.
52. Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009;15(16):5049-5059.
53. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075-1083.
54. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist. 211;16(suppl 1):12-19.
55. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011;10(3):558-565.
56. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
57. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res. 2001;264(1):29-41.